Inactive Instrument

Cytomedix, Inc. Share Price OTC Bulletin Board

Equities

CMXI

US23283B2043

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Cytomedix, Inc.
Sales 2022 112K 8.64M Sales 2023 609K 46.82M Capitalization 24.33M 1.87B
Net income 2022 -3M -231M Net income 2023 -3M -231M EV / Sales 2022 543 x
Net cash position 2022 1.72M 132M Net cash position 2023 673K 51.79M EV / Sales 2023 38.9 x
P/E ratio 2022
-18.9 x
P/E ratio 2023
-7.3 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 41.75%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 61 18/09/08
Chief Operating Officer 58 31/08/08
Members of the board TitleAgeSince
Director/Board Member 67 29/01/09
Chief Executive Officer 61 18/09/08
Director/Board Member 75 06/04/17
More insiders
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
More about the company